Holen Sie sich die Stockscreener-App
7.06
3.98%
0.27
Vorhandelsmarkt:
7.42
0.36
+5.10%
Armata Pharmaceuticals Inc Aktie (ARMP) Neueste Nachrichten
Armata Pharmaceuticals (ARMP) Edges Lower Amid Sector Pressure – Key Levels in FocusPost-Earnings Moves - newsline.com
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
Armata Pharmaceuticals (ARMP) Slips 3.6% as Stock Tests Key Support LevelsPCR Mean Reversion - newsline.com
Armata Pharmaceuticals Slips 2.47% as Bears Test Support Near $7.12Mid Cap Momentum - newsline.com
Armata Pharmaceuticals (ARMP) Climbs 3.62% – Testing Key Resistance Near $8.26Fibonacci Arc - newsline.com
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Significant Earnings Miss Reflects Pre-Revenue Development StageEarnings Cycle Report - newsline.com
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key SupportRectangle Pattern - The Legal Advocate
Armata Pharmaceuticals Q1 2026 Earnings: Deep EPS Miss Masks Strategic Progress, Stock RisesProfitability Analysis - newsline.com
Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Massive EPS Miss as Pre-Revenue Biotech Struggles with Costs - newsline.com
Armata Pharmaceuticals Q1 2026 Earnings: Significant EPS Miss but Stock Rises on Pipeline ProgressFinal Results - Newser
Why Is Armata Pharmaceuticals, Inc. (ARMP) Stock Down Today? - Meyka
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Armata Pharmaceuticals 1Q Loss/Shr $3.16 >ARMP - Moomoo
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
ARMP: Armata Reports Increased Revenue and Focuses on Phase 3 Tr - GuruFocus
Armata Pharmaceuticals (ARMP) Q1 2026: EPS -3.16 Misses Est. -0. - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update - TradingView
Armata Secures New Loan Amid Wider Quarterly Loss - TipRanks
Armata Pharmaceuticals (ARMP) now 82.7% owned by Innoviva after new loan - Stock Titan
Armata Pharmaceuticals, Inc. 1Q 2026: Revenue $789K, EPS ($3.16) — 10-Q Summary - TradingView
Armata (NYSE: ARMP) loss, debt surge and Phase 3 bacteremia trial plan - Stock Titan
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Press Release: Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Moomoo
ARMP Technical Analysis | Trend, Signals & Chart Patterns | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
JonesTrading Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $20 - Moomoo
FDA grants fast track status to Armata’s bacterial infection drug By Investing.com - Investing.com India
Armata Gains FDA Fast Track for AP-SA02 Therapy - TipRanks
FDA grants fast track status to Armata’s bacterial infection drug - Investing.com India
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 - PR Newswire
MSN Money - MSN
The industry tailwinds powering Armata (ARMP) growth (Underperforming) 2026-05-05Continuation Signals - newser.com
Study maps phage in Armata’s treatment candidate for lung infections - Stock Titan
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" - marketscreener.com
ARMP Forecast, Price Target & Analyst Ratings | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
Armata Pharmaceuticals (ARMP) director receives 51,280 stock options at $12.92 - Stock Titan
Director Daniel Gilmer reported as insider at Armata Pharmaceuticals (ARMP) - Stock Titan
Armata Pharmaceuticals : 2026 Annual Meeting Proxy - marketscreener.com
[ARS] Armata Pharmaceuticals, Inc. SEC Filing - Stock Titan
Armata Pharmaceuticals (NASDAQ: ARMP) 2026 proxy details pay, control and going concern risk - Stock Titan
Pfizer Inc. (PFE)Senior Commercial Leader Daniel B. Gilmer, Ph.D. Appointed to Armata Pharmaceuticals Board of DirectorsCertified Trade Ideas - newser.com
Armata Pharmaceuticals Appoints Pfizer Executive Daniel B. Gilmer, Ph.D. to Board to Advance Bacteriophage Therapeutics Commercialization 1 - Minichart
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors - TipRanks
Armata Pharmaceuticals adds Pfizer executive to board - Investing.com
Arm appoints Dr. Daniel Gilmer to Board effective April 24, 2026 - TradingView
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors – Company AnnouncementFT.com - Financial Times
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ARMP (Armata Pharmaceuticals Inc.) Q4 2025 EPS drastically misses analyst estimates, sending its shares down 6.37% today.Geographic Trends - Xã Thanh Hà
ARMP (Armata Pharmaceuticals Inc.) falls 5.64% as drastically wider than expected Q4 2025 net loss spooks investors.Retail Trader Ideas - UBND thành phố Hải Phòng
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):